GSK’s new R&D leader abandons NY-ESO plans and pulls the plug on cell therapy 2.0 alliances after losing confidence – Endpoints News

The FDA’s Cardiovascular and Renal Drugs Advisory Committee will vote tomorrow on whether the benefits of GSK’s daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, outweigh its risks for the treatment of anemia due to chronic kidney disease (CKD). ) in adult patients. about dialysis and about dialysis.

Once hailed as a top drug in the British drugmaker’s late-stage pipeline by former R&D chief Hal Barron, the FDA is now raising serious questions about its benefits given some of its potential risks, noting that it’s “the advice and recommendations of the advisory committee looks into these security issues,” adding:

Endpoints NewsKeep reading Endpoints with a free plan

Instantly unlock this story and join 152,100+ biopharma professionals who read Endpoints daily – and it’s free.


Leave a Comment